BioMarin's Phase 3 PEGASUS Study Of Palynziq In Adolescents With Phenylketonuria Meets Primary Goal

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) Wednesday said its Phase 3 PEGASUS study evaluating Palynziq in adolescents aged 12-17 with phenylketonuria (PKU) met its primary goal.

The study is designed to evaluate the safety and efficacy of Palynziq compared to diet alone in 55 adolescents aged 12-17 with phenylketonuria. The primary endpoints are change in blood Phe concentration and characterization of the safety profile in adolescents.

The drug is already approved to reduce blood Phe concentrations for adults in the U.S., for people 16 and older in the EU, Canada and Brazil, and for people 15 and older in Japan with PKU.